EGFR拮抗剂在结直肠癌治疗中的应用

EGFR inhibitors and colorectal cancer

EGFR活化及其信号通路在结直肠癌生物学中起着重要作用。EGFR靶向药物为结直肠癌的治疗开创了新的方向。与酪氨酸激酶抑制剂相比,单克隆抗体已被证明有很高的疗效。西妥昔单抗作为一线、二线用药及用于化疗耐药的病人都是有效的。作为一线药物时,它的加用还可以提高肝转移灶切除率。

EGFR activation and subsequent signal pathways are critical in colorectal cancer biology. Its targeting with specific drugs has opened a new window in the treatment of this disease. Monoclonal antibodies have a high degree of efficiency opposed to the uselessness of tyrosine - kinase inhibitors. Cetuximab has efficiency from the first line to heavily pretreated patients. In the first line, its addition may increase response rate to chemotherapy, improve liver metastases resection rate.